# Phase 1, Febuxostat XR Relative Bioavailability Study

> **NCT02504320** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 78 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Febuxostat XR 80 mg Capsule F1
- **DRUG:** Febuxostat XR 80 mg Capsule F2
- **DRUG:** Febuxostat XR 80 mg Capsule F3
- **DRUG:** Febuxostat XR 80 mg Capsule F4

## Key facts

- **NCT ID:** NCT02504320
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504320, "Phase 1, Febuxostat XR Relative Bioavailability Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02504320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*